Satellos Bioscience Inc(MSLE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.98 | Insider Own | 28.56% | Shs Outstand | 20.8M | Perf Week | 7.38% |
| Market Cap | 0.21B | Forward P/E | - | EPS next Y | 0.14% | Insider Trans | - | Shs Float | 15.2M | Perf Month | -2.69% |
| Enterprise Value | 0.15B | PEG | - | EPS next Q | -0.59 | Inst Own | 28.77% | Short Float | 0.59% | Perf Quarter | 65.25% |
| Income | -0.03B | P/S | - | EPS this Y | -35.55% | Inst Trans | -0.01% | Short Ratio | 1.65 | Perf Half Y | 13.9% |
| Sales | 0.00B | P/B | 3.39 | EPS next 5Y | -9.33% | ROA | -64.76% | Short Interest | 0.09M | Perf YTD | 65.82% |
| Book/sh | 2.87 | P/C | 3.35 | EPS past 3/5Y | 16.48% 36.03% | ROE | -70.45% | 52W High | -27.21% ($13.39) | Perf Year | 59.31% |
| Cash/sh | 2.91 | P/FCF | - | Sales past 3/5Y | - | ROIC | -57.77% | 52W Low | 83.87% ($5.30) | Perf 3Y | 113.23% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -6.71% | Gross Margin | - | Volatility(W/M) | 7.03% 5.37% | Perf 5Y | -29.35% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.6 | Perf 10Y | -23.92% |
| Dividend Ex-Date | - | Quick Ratio | 11.22 | EPS Q/Q | -43.13% | Profit Margin | - | RSI (14) | 54.22 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.22 | Sales Q/Q | - | SMA20 | 2.27% ($9.53) | Beta | 1.49 | Target Price | $21.81 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | 3.46% ($9.42) | Rel Volume | 0.62 | Prev Close | $10.05 |
| Employees | 18 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -8.53% - | SMA200 | 18.92% ($8.2) | Avg Volume(3M) | 0.05M | Price | $9.75 |
| IPO | 2009/2/19 | Option/Short | No/Yes | Trades | 418 | Volume | 33,421 | Change | -2.99% |
Company
MSLE is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Satellos Biosciences is a clinical-stage biotechnology company founded in Canada in 2018 that develops therapeutics for degenerative muscle diseases by restoring the natural regenerative mechanism of muscle stem cells. Leveraging its proprietary discovery platform, the company is advancing an oral small-molecule candidate into clinical stages for the treatment of Duchenne muscular dystrophy, while continuing its research and development activities primarily in North America.
Over the past 1 year, roughly in the middle
27% below its 1-year high.
MSLE has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -35.5% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +113.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 28.8%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $207M.
MSLE $207M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is MSLE?
MSLE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MSLE?
The market cap of MSLE is approximately $207M, ranking 4,094 within its sector.
What is the 52-week high and low for MSLE?
MSLE has recorded a 52-week high of $13.39 and a low of $5.30.
